Journal of Movement Disorders

Review Articles

Nine Hereditary Movement Disorders First Described in Asia: Their History and Evolution: Priya Jagota, Yoshikazu Ugawa, Zakiyah Aldaajani, Norlinah Mohamed Ibrahim, Hiroyuki Ishiura, Yoshiko Nomura, Shoji Tsuji, Cid Diesta, Nobutaka Hattori, Osamu Onodera, Saeed Bohlega, Amir Al-Din, Shen-Yang Lim, Jee-Young Lee, Beomseok Jeon, Pramod Kumar Pal, Huifang Shang, Shinsuke Fujioka, Prashanth Lingappa Kukkle, Onanong Phokaewvarangkul, Chin-Hsien Lin, Cholpon Shambetova, Roongroj Bhidayasiri; J Mov Disord. 2023;16(3):231-247. Published online June 13, 2023; DOI: https://doi.org/10.14802/jmd.23065

3,932 View
256 Download
1 Crossref

Clinical case studies and reporting are important to the discovery of new disorders and the advancement of medical sciences. Both clinicians and basic scientists play equally important roles leading to treatment discoveries for both cures and symptoms. In the field of movement disorders, exceptional observation of patients from clinicians is imperative, not just for phenomenology but also for the variable occurrences of these disorders, along with other signs and symptoms, throughout the day and the disease course. The Movement Disorders in Asia Task Force (TF) was formed to help enhance and promote collaboration and research on movement disorders within the region. As a start, the TF has reviewed the original studies of the movement disorders that were preliminarily described in the region. These include nine disorders that were first described in Asia: Segawa disease, PARK-Parkin, X-linked dystonia-parkinsonism, dentatorubral-pallidoluysian atrophy, Woodhouse-Sakati syndrome, benign adult familial myoclonic epilepsy, Kufor-Rakeb disease, tremulous dystonia associated with mutation of the calmodulin-binding transcription activator 2 gene, and paroxysmal kinesigenic dyskinesia. We hope that the information provided will honor the original researchers and help us learn and understand how earlier neurologists and basic scientists together discovered new disorders and made advances in the field, which impact us all to this day.

Citations

Citations to this article as recorded by

Genetic heterogeneity of early onset Parkinson disease: The dilemma of clinico-genetic correlation
Roopa Rajan, Vikram V. Holla, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal
Parkinsonism & Related Disorders.2024; : 107146. CrossRef

Historical and More Common Nongenetic Movement Disorders From Asia: Norlinah Mohamed Ibrahim, Priya Jagota, Pramod Kumar Pal, Roongroj Bhidayasiri, Shen-Yang Lim, Yoshikazu Ugawa, Zakiyah Aldaajani, Beomseok Jeon, Shinsuke Fujioka, Jee-Young Lee, Prashanth Lingappa Kukkle, Huifang Shang, Onanong Phokaewvarangkul, Cid Diesta, Cholpon Shambetova, Chin-Hsien Lin; J Mov Disord. 2023;16(3):248-260. Published online June 9, 2023; DOI: https://doi.org/10.14802/jmd.22224

2,874 View
141 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material

Nongenetic movement disorders are common throughout the world. The movement disorders encountered may vary depending on the prevalence of certain disorders across various geographical regions. In this paper, we review historical and more common nongenetic movement disorders in Asia. The underlying causes of these movement disorders are diverse and include, among others, nutritional deficiencies, toxic and metabolic causes, and cultural Latah syndrome, contributed by geographical, economic, and cultural differences across Asia. The industrial revolution in Japan and Korea has led to diseases related to environmental toxin poisoning, such as Minamata disease and β-fluoroethyl acetate-associated cerebellar degeneration, respectively, while religious dietary restriction in the Indian subcontinent has led to infantile tremor syndrome related to vitamin B12 deficiency. In this review, we identify the salient features and key contributing factors in the development of these disorders.

Citations

Citations to this article as recorded by

Diabetic striatopathy and other acute onset de novo movement disorders in hyperglycemia
Subhankar Chatterjee, Ritwik Ghosh, Payel Biswas, Shambaditya Das, Samya Sengupta, Souvik Dubey, Biman Kanti Ray, Alak Pandit, Julián Benito-León, Rana Bhattacharjee
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(3): 102997. CrossRef
Tremors in Infantile Tremor Syndrome Mimicking Epilepsia Partialis Continua
Tonyot Gailson, Pradeep Kumar Gunasekaran, Arushi Gahlot Saini, Chaithanya Reddy
Journal of Movement Disorders.2024; 17(3): 351. CrossRef

Original Article

Clinical Characteristics, Genetic Features, and Long-Term Outcome of Wilson’s Disease in a Taiwanese Population: An 11-Year Follow-Up Study: Sung-Pin Fan, Yih-Chih Kuo, Ni-Chung Lee, Yin-Hsiu Chien, Wuh-Liang Hwu, Yu-Hsuan Huang, Han-I Lin, Tai-Chung Tseng, Tung-Hung Su, Shiou-Ru Tzeng, Chien-Ting Hsu, Huey-Ling Chen, Chin-Hsien Lin, Yen-Hsuan Ni; J Mov Disord. 2023;16(2):168-179. Published online March 6, 2023; DOI: https://doi.org/10.14802/jmd.22161

2,981 View
137 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material

Objective
aaWilson’s disease (WD) is a rare genetic disorder of copper metabolism, and longitudinal follow-up studies are limited. We performed a retrospective analysis to determine the clinical characteristics and long-term outcomes in a large WD cohort.
Methods
aaMedical records of WD patients diagnosed from 2006–2021 at National Taiwan University Hospital were retrospectively evaluated for clinical presentations, neuroimages, genetic information, and follow-up outcomes.
Results
aaThe present study enrolled 123 WD patients (mean follow-up: 11.12 ± 7.41 years), including 74 patients (60.2%) with hepatic features and 49 patients (39.8%) with predominantly neuropsychiatric symptoms. Compared to the hepatic group, the neuropsychiatric group exhibited more Kayser-Fleischer rings (77.6% vs. 41.9%, p < 0.01), lower serum ceruloplasmin levels (4.9 ± 3.9 vs. 6.3 ± 3.9 mg/dL, p < 0.01), smaller total brain and subcortical gray matter volumes (p < 0.0001), and worse functional outcomes during follow-up (p = 0.0003). Among patients with available DNA samples (n = 59), the most common mutations were p.R778L (allelic frequency of 22.03%) followed by p.P992L (11.86%) and p.T935M (9.32%). Patients with at least one allele of p.R778L had a younger onset age (p = 0.04), lower ceruloplasmin levels (p < 0.01), lower serum copper levels (p = 0.03), higher percentage of the hepatic form (p = 0.03), and a better functional outcome during follow-up (p = 0.0012) compared to patients with other genetic variations.
Conclusion
aaThe distinct clinical characteristics and long-term outcomes of patients in our cohort support the ethnic differences regarding the mutational spectrum and clinical presentations in WD.

Citations

Citations to this article as recorded by

Topographical metal burden correlates with brain atrophy and clinical severity in Wilson's disease
Sung-Pin Fan, Ya-Fang Chen, Cheng-Hsuan Li, Yih-Chih Kuo, Ni-Chung Lee, Yin-Hsiu Chien, Wuh-Liang Hwu, Tai-Chung Tseng, Tung-Hung Su, Chien-Ting Hsu, Huey-Ling Chen, Chin-Hsien Lin, Yen-Hsuan Ni
NeuroImage.2024; 299: 120829. CrossRef
ATP7B Gene Variant Profile İdentified by NGS in Wilson’s Disease
Orhan Gorukmez, Taner Özgür, Ozlem Gorukmez, Ali Topak
Fetal and Pediatric Pathology.2023; 42(6): 891. CrossRef

Review Article

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease: Han-Lin Chiang, Chin-Hsien Lin; J Mov Disord. 2019;12(2):67-83. Published online May 30, 2019; DOI: https://doi.org/10.14802/jmd.18067

16,905 View
760 Download
68 Web of Science
67 Crossref

Abstract PDF

Parkinson’s disease (PD) is a common neurodegenerative disorder arising from an interplay between genetic and environmental risk factors. Studies have suggested that the pathological hallmarks of intraneuronal α-synuclein aggregations may start from the olfactory bulb and the enteric nervous system of the gut and later propagate to the brain via the olfactory tract and the vagus nerve. This hypothesis correlates well with clinical symptoms, such as constipation, that may develop up to 20 years before the onset of PD motor symptoms. Recent interest in the gut–brain axis has led to vigorous research into the gastrointestinal pathology and gut microbiota changes in patients with PD. In this review, we provide current clinical and pathological evidence of gut involvement in PD by summarizing the changes in gut microbiota composition and gut inflammation associated with its pathogenesis.

Citations

Citations to this article as recorded by

Buty and the beast: the complex role of butyrate in Parkinson’s disease
Joshua D. Elford, Nanette Becht, Johan Garssen, Aletta D. Kraneveld, Paula Perez-Pardo
Frontiers in Pharmacology.2024;[Epub] CrossRef
Acupuncture ameliorates depression-like behavior of poststroke depression model rats through the regulation of gut microbiota and NLRP3 inflammasome in the colon
Wa Cai, Xi-Fang Wei, Jing-Ruo Zhang, Larissa Tao, Dong Li, Kun Zhang, Wei-Dong Shen
NeuroReport.2024; 35(14): 883. CrossRef
Intestinal Barrier Function and Neurodegenerative Disease
Shijing Wu, Liangfang Yang, Yiwei Fu, Zhimin Liao, De Cai, Zhou Liu
CNS & Neurological Disorders - Drug Targets.2024; 23(9): 1134. CrossRef
Advice to People with Parkinson’s in My Clinic: Probiotics and Prebiotics
Jia Wei Hor, Tzi Shin Toh, Shen-Yang Lim, Ai Huey Tan
Journal of Parkinson's Disease.2024; : 1. CrossRef
The Role of the Gut Microbiota in Sanfilippo Syndrome’s Physiopathology: An Approach in Two Affected Siblings
Raquel Barbero-Herranz, María Garriga-García, Ana Moreno-Blanco, Esther Palacios, Pedro Ruiz-Sala, Saioa Vicente-Santamaría, Sinziana Stanescu, Amaya Belanger-Quintana, Guillem Pintos-Morell, Beatriz Arconada, Rosa del Campo, José Avendaño-Ortiz
International Journal of Molecular Sciences.2024; 25(16): 8856. CrossRef
Adipose tissue, systematic inflammation, and neurodegenerative diseases
AnaPaula de A. Boleti, PedroHenrique de O. Cardoso, BrenoEmanuel F. Frihling, PatríciaSouza e Silva, LuizFilipe R. N. de Moraes, Ludovico Migliolo
Neural Regeneration Research.2023; 18(1): 38. CrossRef
Parkinson's Disease: A Multisystem Disorder
Helena Nunes Costa, Ana Raquel Esteves, Nuno Empadinhas, Sandra Morais Cardoso
Neuroscience Bulletin.2023; 39(1): 113. CrossRef
Brain modulation by the gut microbiota: From disease to therapy
Sarmistha Mitra, Raju Dash, Amena Al Nishan, Sarmin Ummey Habiba, Il Soo Moon
Journal of Advanced Research.2023; 53: 153. CrossRef
Plasma Metabolic Analysis Reveals the Dysregulation of Short-Chain Fatty Acid Metabolism in Parkinson’s Disease
Ao Qi, Lulu Liu, Junjie Zhang, Simei Chen, Simin Xu, Yusen Chen, Lijiang Zhang, Chun Cai
Molecular Neurobiology.2023; 60(5): 2619. CrossRef
Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study
Herbert L. DuPont, Jessika Suescun, Zhi-Dong Jiang, Eric L. Brown, Heather T. Essigmann, Ashley S. Alexander, Andrew W. DuPont, Tehseen Iqbal, Netanya S. Utay, Michael Newmark, Mya C. Schiess
Frontiers in Neurology.2023;[Epub] CrossRef
Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases
Mohamed S. Attia, Ahmed Yahya, Nada Abdel Monaem, Shereen A. Sabry
Saudi Pharmaceutical Journal.2023; 31(3): 417. CrossRef
GSDMD in peripheral myeloid cells regulates microglial immune training and neuroinflammation in Parkinson's disease
Bingwei Wang, Yan Ma, Sheng Li, Hang Yao, Mingna Gu, Ying Liu, You Xue, Jianhua Ding, Chunmei Ma, Shuo Yang, Gang Hu
Acta Pharmaceutica Sinica B.2023; 13(6): 2663. CrossRef
Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson’s disease
Júlio César Claudino dos Santos, Leandro Freitas Oliveira, Felipe Micelli Noleto, Camilla Teixeira Pinheiro Gusmão, Gerly Anne de Castro Brito, Glauce Socorro de Barros Viana
Neural Regeneration Research.2023; 18(12): 2611. CrossRef
Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson’s Disease from Mice to Human
Martina Montanari, Paola Imbriani, Paola Bonsi, Giuseppina Martella, Antonella Peppe
Biomedicines.2023; 11(6): 1560. CrossRef
Effects of gut microbiota on neurodegenerative diseases
Saima Khatoon, Nida Kalam, Summya Rashid, Gulnaz Bano
Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes
Frances Widjaja, Ivonne M. C. M. Rietjens
Biomedicines.2023; 11(10): 2658. CrossRef
Association between the risk and severity of Parkinson’s disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis
Yuxin Quan, Jisen Xu, Qing Xu, Zhiqing Guo, Ruwei Ou, Huifang Shang, Qianqian Wei
Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Oral pathogens exacerbate Parkinson’s disease by promoting Th1 cell infiltration in mice
Xue-Bing Bai, Shuo Xu, Lu-Jun Zhou, Xiao-Qian Meng, Yu-Lin Li, Yan-Lin Chen, Yi-Han Jiang, Wen-Zhen Lin, Bo-Yan Chen, Lin-Juan Du, Guo-Cai Tian, Yan Liu, Sheng-Zhong Duan, Ya-Qin Zhu
Microbiome.2023;[Epub] CrossRef
The intestinal luminal sources of α-synuclein: a gastroenterologist perspective
Aaron Lerner
Nutrition Reviews.2022; 80(2): 282. CrossRef
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway
Chin‐Hsien Lin, Han‐Yi Lin, En‐Pong Ho, Yi‐Ci Ke, Mei‐Fang Cheng, Chyng‐Yann Shiue, Chi‐Han Wu, Peng‐Hsiang Liao, Angela Yu‐Huey Hsu, Li‐An Chu, Ya‐Ding Liu, Ya‐Hui Lin, Yi‐Cheng Tai, Chia‐Tung Shun, Han‐Mo Chiu, Ming‐Shiang Wu
Movement Disorders.2022; 37(4): 745. CrossRef
Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson’s disease
Ehraz Anis, Aoji Xie, Lena Brundin, Patrik Brundin
Trends in Endocrinology & Metabolism.2022; 33(2): 147. CrossRef
Animal models of brain-first and body-first Parkinson's disease
Nathalie Van Den Berge, Ayse Ulusoy
Neurobiology of Disease.2022; 163: 105599. CrossRef
Microbiome Changes in Humans with Parkinson’s Disease after Photobiomodulation Therapy: A Retrospective Study
Brian Bicknell, Ann Liebert, Craig S. McLachlan, Hosen Kiat
Journal of Personalized Medicine.2022; 12(1): 49. CrossRef
Passive Immunization in Alpha-Synuclein Preclinical Animal Models
Jonas Folke, Nelson Ferreira, Tomasz Brudek, Per Borghammer, Nathalie Van Den Berge
Biomolecules.2022; 12(2): 168. CrossRef
Dietary Succinoglycan Riclin Improves Glycemia Control in Mice with Type 2 Diabetes
Zhao Ding, Yang Zhao, Junhao Liu, Wenhao Ge, Xi Xu, Shiming Wang, Jianfa Zhang
Journal of Agricultural and Food Chemistry.2022; 70(6): 1819. CrossRef
Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling
Sevag Hamamah, Armin Aghazarian, Anthony Nazaryan, Andras Hajnal, Mihai Covasa
Biomedicines.2022; 10(2): 436. CrossRef
Distribution of α-Synuclein Aggregation in the Peripheral Tissues
Yan-yan Li, Tian-tian Zhou, Yi Zhang, Nai-Hong Chen, Yu-He Yuan
Neurochemical Research.2022; 47(12): 3627. CrossRef
Effects of Subdiaphragmatic Vagotomy in the MPTP-induced Neurotoxicity in the Striatum and Colon of Mice
Jiajing Shan, Youge Qu, Jiancheng Zhang, Li Ma, Kenji Hashimoto
Clinical Psychopharmacology and Neuroscience.2022; 20(2): 389. CrossRef
Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies
Mie Kristine Just, Hjalte Gram, Vasileios Theologidis, Poul Henning Jensen, K. Peter R. Nilsson, Mikael Lindgren, Karoline Knudsen, Per Borghammer, Nathalie Van Den Berge
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients
María Romo-Vaquero, Emiliano Fernández-Villalba, Ana-Luisa Gil-Martinez, Lorena Cuenca-Bermejo, Juan Carlos Espín, María Trinidad Herrero, María Victoria Selma
Food & Function.2022; 13(11): 6306. CrossRef
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease
Hiroshi Nishiwaki, Mikako Ito, Tomonari Hamaguchi, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Takumi Yoshida, Hiroyuki Hanada, Ichiro Takeuchi, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
npj Parkinson's Disease.2022;[Epub] CrossRef
Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes
Amnon A. Berger, Ariel Winnick, Jonathan Izygon, Binil M. Jacob, Jessica S. Kaye, Rachel J. Kaye, Elisa E. Neuchat, Adam M. Kaye, Edward S. Alpaugh, Elyse M. Cornett, Andrew H. Han, Alan D. Kaye
Health Psychology Research.2022;[Epub] CrossRef
The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases
George Tsafaras, Veerle Baekelandt
Neurobiology of Disease.2022; 172: 105806. CrossRef
What Is the Prognostic Significance of Rapid Eye Movement Sleep Without Atonia in a Polysomnogram?
Frank Ralls, Lisa Cutchen, Madeleine M. Grigg-Damberger
Journal of Clinical Neurophysiology.2022; 39(5): 346. CrossRef
Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism
Jose Ivo A. Beserra-Filho, Amanda Maria-Macêdo, Suellen Silva-Martins, Ana Cláudia Custódio-Silva, Beatriz Soares-Silva, Sara Pereira Silva, Rafael Herling Lambertucci, Adriano Antunes de Souza Araújo, Angélica Maria Lucchese, Lucindo J. Quintans-Júnior,
Metabolic Brain Disease.2022; 37(7): 2331. CrossRef
Oral and gut dysbiosis leads to functional alterations in Parkinson’s disease
Sungyang Jo, Woorim Kang, Yun Su Hwang, Seung Hyun Lee, Kye Won Park, Mi Sun Kim, Hyunna Lee, Hyung Jeong Yoon, Yoo Kyoung Park, Mauricio Chalita, Je Hee Lee, Hojun Sung, Jae-Yun Lee, Jin-Woo Bae, Sun Ju Chung
npj Parkinson's Disease.2022;[Epub] CrossRef
Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson’s Disease
Ritu Soni, Jigna Shah
ACS Chemical Neuroscience.2022; 13(15): 2240. CrossRef
Therapeutic potential of short-chain fatty acid production by gut microbiota in neurodegenerative disorders
Sarika Yadav, Ashish Dwivedi, Anurag Tripathi, Amit Kumar Tripathi
Nutrition Research.2022; 106: 72. CrossRef
Development of neurodegenerative disorders and the role of gut
Woong-Woo Lee
Journal of Geriatric Neurology.2022; 1(2): 53. CrossRef
What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review
Bruno Bonnechère, Najaf Amin, Cornelia van Duijn
International Journal of Molecular Sciences.2022; 23(22): 13665. CrossRef
Gut microbiota in dementia with Lewy bodies
Hiroshi Nishiwaki, Jun Ueyama, Kenichi Kashihara, Mikako Ito, Tomonari Hamaguchi, Tetsuya Maeda, Yoshio Tsuboi, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
npj Parkinson's Disease.2022;[Epub] CrossRef
Gut dysbiosis in stroke and its implications on Alzheimer’s disease‐like cognitive dysfunction
Justin Cho, You Jeong Park, Bella Gonzales‐Portillo, Madeline Saft, Blaise Cozene, Nadia Sadanandan, Cesar V. Borlongan
CNS Neuroscience & Therapeutics.2021; 27(5): 505. CrossRef
Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease
Szu-Ju Chen, Yu-Chiao Chi, Chang-Han Ho, Wei-Shiung Yang, Chin-Hsien Lin
Journal of Parkinson's Disease.2021; 11(3): 1129. CrossRef
Parkinson's disease and the gut: Models of an emerging relationship
Adam J. Bindas, Subhash Kulkarni, Ryan A. Koppes, Abigail N. Koppes
Acta Biomaterialia.2021; 132: 325. CrossRef
Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats
Nathalie Van Den Berge, Nelson Ferreira, Trine Werenberg Mikkelsen, Aage Kristian Olsen Alstrup, Gültekin Tamgüney, Páll Karlsson, Astrid Juhl Terkelsen, Jens Randel Nyengaard, Poul Henning Jensen, Per Borghammer
Brain.2021; 144(6): 1853. CrossRef
Desulfovibrio Bacteria Are Associated With Parkinson’s Disease
Kari E. Murros, Vy A. Huynh, Timo M. Takala, Per E. J. Saris
Frontiers in Cellular and Infection Microbiology.2021;[Epub] CrossRef
“Janus-Faced” α-Synuclein: Role in Parkinson’s Disease
Bipul Ray, Arehally M. Mahalakshmi, Sunanda Tuladhar, Abid Bhat, Asha Srinivasan, Christophe Pellegrino, Anbarasu Kannan, Srinivasa Rao Bolla, Saravana Babu Chidambaram, Meena Kishore Sakharkar
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease
Jonas Ghyselinck, Lynn Verstrepen, Frédéric Moens, Pieter Van Den Abbeele, Arnout Bruggeman, Jawal Said, Barry Smith, Lynne Ann Barker, Caroline Jordan, Valentina Leta, K. Ray Chaudhuri, Abdul W. Basit, Simon Gaisford
International Journal of Pharmaceutics: X.2021; 3: 100087. CrossRef
The Role of The Gut Microbiome in Parkinson’s Disease
Amy Gallop, James Weagley, Saif-ur-Rahman Paracha, George Grossberg
Journal of Geriatric Psychiatry and Neurology.2021; 34(4): 253. CrossRef
The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease
Gianfranco Natale, Larisa Ryskalin, Gabriele Morucci, Gloria Lazzeri, Alessandro Frati, Francesco Fornai
Life.2021; 11(8): 732. CrossRef
Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson’s disease mice by gut microbiome
Jiajing Shan, Youge Qu, Siming Wang, Yan Wei, Lijia Chang, Li Ma, Kenji Hashimoto
Brain Research Bulletin.2021; 177: 103. CrossRef
Cholecystectomy and subsequent risk of Parkinson’s disease: a nationwide retrospective cohort study
Ryul Kim, Jee-Young Lee, Sanghyun Park, Kyungdo Han, Cheol Min Shin
npj Parkinson's Disease.2021;[Epub] CrossRef
Benefits of Helicobacter pylori Eradication on Extragastric Diseases
Tae Jun Kim, Hyuk Lee
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(4): 275. CrossRef
Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson’s disease
Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanisław Szlufik, Dariusz Koziorowski, Joanna Giebułtowicz
Clinica Chimica Acta.2020; 501: 165. CrossRef
The microbiome-gut-brain axis in acute and chronic brain diseases
Corinne Benakis, Camille Martin-Gallausiaux, Jean-Pierre Trezzi, Philip Melton, Arthur Liesz, Paul Wilmes
Current Opinion in Neurobiology.2020; 61: 1. CrossRef
The progress of gut microbiome research related to brain disorders
Sibo Zhu, Yanfeng Jiang, Kelin Xu, Mei Cui, Weimin Ye, Genming Zhao, Li Jin, Xingdong Chen
Journal of Neuroinflammation.2020;[Epub] CrossRef
Minireview on the Relations between Gut Microflora and Parkinson’s Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities
Ovidiu-Dumitru Ilie, Alin Ciobica, Jack McKenna, Bogdan Doroftei, Ioannis Mavroudis, Tuane B. Sampaio
Oxidative Medicine and Cellular Longevity.2020; 2020: 1. CrossRef
Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?
Carolina Pellegrini, Luca Antonioli, Vincenzo Calderone, Rocchina Colucci, Matteo Fornai, Corrado Blandizzi
Progress in Neurobiology.2020; 191: 101806. CrossRef
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease
Hiroshi Nishiwaki, Mikako Ito, Tomohiro Ishida, Tomonari Hamaguchi, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Teppei Shimamura, Hiroshi Mori, Ken Kurokawa, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
Movement Disorders.2020; 35(9): 1626. CrossRef
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
Maria Fouka, Panagiota Mavroeidi, Grigoria Tsaka, Maria Xilouri
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Role of Carbon Monoxide in Host–Gut Microbiome Communication
Christopher P. Hopper, Ladie Kimberly De La Cruz, Kristin V. Lyles, Lauren K. Wareham, Jack A. Gilbert, Zehava Eichenbaum, Marcin Magierowski, Robert K. Poole, Jakob Wollborn, Binghe Wang
Chemical Reviews.2020; 120(24): 13273. CrossRef
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Chrysoula Marogianni, Maria Sokratous, Efthimios Dardiotis, Georgios M. Hadjigeorgiou, Dimitrios Bogdanos, Georgia Xiromerisiou
International Journal of Molecular Sciences.2020; 21(22): 8421. CrossRef
Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson’s Disease
Tennekoon B. Karunaratne, Chijioke Okereke, Marissa Seamon, Sharad Purohit, Chandramohan Wakade, Amol Sharma
Nutrients.2020; 13(1): 28. CrossRef
Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson’s Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder
Hiroshi Nishiwaki, Tomonari Hamaguchi, Mikako Ito, Tomohiro Ishida, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Teppei Shimamura, Hiroshi Mori, Ken Kurokawa, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno, Chaysavanh Manichanh
mSystems.2020;[Epub] CrossRef
The Intestinal Barrier in Parkinson’s Disease: Current State of Knowledge
Sven C. D. van IJzendoorn, Pascal Derkinderen, Teus van Laar
Journal of Parkinson's Disease.2019; 9(s2): S323. CrossRef
Medical management, prevention and mitigation of environmental risks factors in Neurology
J. Reis, G.C. Román, M. Giroud, V.S. Palmer, P.S. Spencer
Revue Neurologique.2019; 175(10): 698. CrossRef
Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain
Yaoyu Pu, Lijia Chang, Youge Qu, Siming Wang, Kai Zhang, Kenji Hashimoto
Aging.2019; 11(17): 6915. CrossRef

First
Prev
Page of 1
Next
Last

Search